Obscure X chromosome protein emerges as key driver in several cancers

A little-known protein encoded on the X chromosome is attracting growing attention for its potential role in cancer development and treatment. A new review highlights the expanding importance of CXorf67, an epigenetic regulator that influences gene activity, DNA repair processes, and tumor behavior across several malignancies, including aggressive brain tumors, osteosarcoma, lung cancer, endometrial stromal sarcoma, and Merkel cell carcinoma.

Although CXorf67 was identified years ago during efforts to map the human genome, its biological function remained largely unclear. Recent discoveries have revealed that the protein interacts with key components of the Polycomb Repressive Complex 2 (PRC2), a major regulator of gene silencing. Through this interaction, CXorf67 influences the epigenetic marker H3K27me3, which plays a crucial role in controlling chromatin structure and gene expression. By disrupting this pathway, CXorf67 can alter cellular identity and activate programs associated with cancer development.

The review highlights particularly strong evidence for the involvement of CXorf67 in posterior fossa ependymoma, an aggressive childhood brain tumor. High levels of CXorf67 are linked to widespread epigenetic changes that support tumor growth and survival. Similar mechanisms have been identified in diffuse midline glioma, another highly aggressive pediatric brain cancer. In both diseases, CXorf67 acts in a manner that resembles the cancer-associated H3K27M histone mutation, producing profound effects on gene regulation and tumor biology.

Beyond its role in epigenetics, CXorf67 also appears to influence the cellular response to DNA damage. The protein can interfere with the BRCA1-PALB2-BRCA2 repair pathway, reducing the ability of cells to accurately repair double-strand DNA breaks. This defect may increase tumor vulnerability to therapies that target DNA repair mechanisms, creating new opportunities for precision medicine approaches.

Evidence is also emerging for the involvement of CXorf67 in osteosarcoma, where it promotes abnormal cellular reprogramming and disrupts normal differentiation pathways. In endometrial stromal sarcoma, CXorf67 participates in cancer-associated fusion genes that may alter important chromatin-regulating complexes. The protein has additionally been identified as a potential cancer-testis antigen in non-small cell lung cancer, raising interest in its possible role as an immunotherapy target.

Several therapeutic strategies may ultimately exploit CXorf67-related vulnerabilities. The review highlights particular interest in PARP inhibitors, EZH2 inhibitors, and HDAC inhibitors, all of which target pathways affected by CXorf67 activity. While no treatments currently target CXorf67 directly, its restricted expression pattern and central role in cancer-associated epigenetic regulation make it an attractive candidate for future drug development.